{"id":"csl425","safety":{"commonSideEffects":[{"rate":null,"effect":"Injection site reactions"},{"rate":null,"effect":"Fever"},{"rate":null,"effect":"Upper respiratory tract infection"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"anthropic-haiku","explanation":"CSL425 binds to the fusion (F) protein on the surface of RSV, blocking the virus's ability to enter and infect host cells. By providing passive immunization through direct viral neutralization, the antibody aims to prevent RSV disease in vulnerable populations. This approach offers immediate protection without requiring the host immune system to generate its own antibody response.","oneSentence":"CSL425 is a recombinant human monoclonal antibody that targets and neutralizes respiratory syncytial virus (RSV) to prevent infection.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T03:29:38.708Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Prevention of respiratory syncytial virus (RSV) disease in infants and young children"}]},"trialDetails":[{"nctId":"NCT00938639","phase":"PHASE2","title":"A Clinical Trial of CSL's 2009 H1N1 Influenza Vaccine (CSL425) in Healthy Adults","status":"COMPLETED","sponsor":"Seqirus","startDate":"2009-07","conditions":"Influenza Caused by the Novel Influenza A (H1N1) Virus","enrollment":240},{"nctId":"NCT00940108","phase":"PHASE2","title":"A Clinical Trial of CSL's 2009 H1N1 Influenza Vaccine (CSL425) in Healthy Children","status":"COMPLETED","sponsor":"Seqirus","startDate":"2009-08","conditions":"Influenza Caused by the Novel Influenza A (H1N1) Virus","enrollment":370},{"nctId":"NCT00958243","phase":"PHASE2","title":"A Clinical Trial of CSL's 2009 H1N1 Influenza Vaccine (CSL425) in a Healthy Pediatric Population in the USA","status":"COMPLETED","sponsor":"Seqirus","startDate":"2009-08","conditions":"Influenza","enrollment":473},{"nctId":"NCT00958126","phase":"PHASE2","title":"A Clinical Trial of CSL's 2009 H1N1 Influenza Vaccine (CSL425) in Healthy Adults in the USA","status":"COMPLETED","sponsor":"Seqirus","startDate":"2009-08","conditions":"Influenza","enrollment":1313}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_2","status":"active","brandName":"CSL425","genericName":"CSL425","companyName":"Seqirus","companyId":"seqirus","modality":"Biologic","firstApprovalDate":"","aiSummary":"CSL425 is a recombinant human monoclonal antibody that targets and neutralizes respiratory syncytial virus (RSV) to prevent infection. Used for Prevention of respiratory syncytial virus (RSV) disease in infants and young children.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}